Mohammed M. Milhem
Impact in
- Cancer Research top 0.1%
- Cancer Genomics and Diagnostics
- Oncology top 0.1%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
Papers in
- Oncology 79
- Cancer Immunotherapy and Biomarkers 29
- CAR-T cell therapy research 28
- Cutaneous Melanoma Detection and Management 17
-
- Sarcoma Diagnosis and Treatment 28
- Co-authors
- Claus Garbe (7 shared papers)Igor J. Puzanov (9 shared papers)Brian Andrew Van Tine (8 shared papers)Robert H.I. Andtbacka (8 shared papers)Howard L. Kaufman (7 shared papers)Lisa Chen (5 shared papers)Omid Hamid (6 shared papers)Varun Monga (30 shared papers)
- Journals
- Annals of Oncology (14 papers)Cell Reports (12 papers)Cell (9 papers)Cancers (9 papers)Journal for ImmunoTherapy of Cancer (8 papers)
- Partner nations
- United StatesFranceGermany
In The Last Decade
Mohammed M. Milhem
187 papers receiving 31.6k citations
Mohammed M. Milhem's Hit Papers
Peers
Comparison fields: 5 of 164
- Cancer Research 6.8k
- Oncology 10.9k
- Molecular Biology 14.8k
- Immunology 4.1k
- Pulmonary and Respiratory Medicine 5.7k
Countries citing papers authored by Mohammed M. Milhem
This map shows the geographic impact of Mohammed M. Milhem's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mohammed M. Milhem with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mohammed M. Milhem more than expected).
Fields of papers citing papers by Mohammed M. Milhem
This network shows the impact of papers produced by Mohammed M. Milhem. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mohammed M. Milhem. The network helps show where Mohammed M. Milhem may publish in the future.
Co-authors
The 25 scholars most cited alongside Mohammed M. Milhem, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 195 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics Hit paper breakdown → | 2018 | 2602 |
| 2 | Oncogenic Signaling Pathways in The Cancer Genome Atlas Hit paper breakdown → | 2018 | 2334 |
| 3 | Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma Hit paper breakdown → | 2015 | 2149 |
| 4 | Improved Survival with MEK Inhibition in BRAF-Mutated Melanoma Hit paper breakdown → | 2012 | 1820 |
| 5 | Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer Hit paper breakdown → | 2018 | 1720 |
| 6 | Comprehensive Characterization of Cancer Driver Genes and Mutations Hit paper breakdown → | 2018 | 1714 |
| 7 | Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation Hit paper breakdown → | 2018 | 1617 |
| 8 | Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group Hit paper breakdown → | 2012 | 1225 |
| 9 | Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas Hit paper breakdown → | 2018 | 810 |
| 10 | Genomic and Functional Approaches to Understanding Cancer Aneuploidy Hit paper breakdown → | 2018 | 749 |
| 11 | Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients Hit paper breakdown → | 2018 | 685 |
| 12 | Efficacy and Safety of Trabectedin or Dacarbazine for Metastatic Liposarcoma or Leiomyosarcoma After Failure of Conventional Chemotherapy: Results of a Phase III Randomized Multicenter Clinical Trial Hit paper breakdown → | 2015 | 678 |
| 13 | Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma Hit paper breakdown → | 2021 | 670 |
| 14 | Pathogenic Germline Variants in 10,389 Adult Cancers Hit paper breakdown → | 2018 | 606 |
| 15 | Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials Hit paper breakdown → | 2018 | 603 |
| 16 | Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines Hit paper breakdown → | 2018 | 583 |
| 17 | The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma Hit paper breakdown → | 2018 | 569 |
| 18 | Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma Hit paper breakdown → | 2017 | 532 |
| 19 | Talimogene Laherparepvec in Combination With Ipilimumab in Previously Untreated, Unresectable Stage IIIB-IV Melanoma Hit paper breakdown → | 2016 | 489 |
| 20 | A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers Hit paper breakdown → | 2018 | 456 |
About Mohammed M. Milhem
Mohammed M. Milhem is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Immunology and Molecular Biology, having authored 195 papers that have together received 32.0k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (29 papers), CAR-T cell therapy research (28 papers), Sarcoma Diagnosis and Treatment (28 papers), Immunotherapy and Immune Responses (20 papers), Melanoma and MAPK Pathways (20 papers), Cancer Genomics and Diagnostics (19 papers), Cutaneous Melanoma Detection and Management (17 papers) and Virus-based gene therapy research (14 papers). The work is most often cited by research in Cancer Research (6.8k citations), Oncology (10.9k citations), Molecular Biology (14.8k citations), Immunology (4.1k citations) and Pulmonary and Respiratory Medicine (5.7k citations). Mohammed M. Milhem has collaborated with scholars based in United States, France and Germany. Frequent co-authors include Claus Garbe, Igor J. Puzanov, Brian Andrew Van Tine, Robert H.I. Andtbacka, Howard L. Kaufman, Lisa Chen, Omid Hamid, Varun Monga, Paul Nathan and Dirk Schadendorf. Their work appears in journals such as Annals of Oncology, Cell Reports, Cell, Cancers and Journal for ImmunoTherapy of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.